Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 20/20 | 1.00 |
| ▸ | TYRO3 | Q06418 | 19/20 | 1.00 |
| ▸ | GAS6 | Q14393 | 18/20 | 1.00 |
| ▸ | FLT3 | P36888 | 16/20 | 1.00 |
| ▸ | AXL | P30530 | 3/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16435518 | 0.94 | TYRO3 (1.00) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL16438297 | 0.92 | MERTK (1.00) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL16435508 | 0.92 | MERTK (1.00) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL16435472 | 0.89 | MERTK (1.00) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL16438335 | 0.89 | MERTK (1.00) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL16435496 | 0.88 | MERTK (1.00) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL16435499 | 0.87 | TYRO3 (1.00) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL16428938 | 0.86 | TYRO3 (1.00) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL16428939 | 0.86 | TYRO3 (1.00) | MERTKTYRO3GAS6FLT3AXL | |
| SCHEMBL16435442 | 0.86 | TYRO3 (1.00) | MERTKTYRO3GAS6FLT3AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9649309-B2 | Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649309-B2 | Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-05-16 | — | — | US | disclosed |
| US-9567326-B2 | Pyrimidine compounds for the treatment of cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567326-B2 | Pyrimidine compounds for the treatment of cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-02-14 | — | — | US | disclosed |
| WO-2015157127-A1 | THERAPUETIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150290194-A1 | THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-15 | — | — | US | disclosed |
| US-20150290194-A1 | THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-15 | — | — | US | disclosed |
| US-20150038481-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-05 | — | — | US | disclosed |
| US-20150038481-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290194-A1 | THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | MERTK, FLT3, TK1 | MERTK 1/4885TYRO3 41/4885GAS6 714/4885 |
| US-20150038481-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | DPYD, TYMP, TYMS | MERTK 2234/4885TYRO3 845/4885GAS6 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.